Paxlovid as a potential treatment for long COVID
MW McCarthy - Expert Opinion on Pharmacotherapy, 2023 - Taylor & Francis
ABSTRACT Introduction On 31 July 2023, the United States Department of Health and
Human Services announced the formation of the Office of Long COVID Research and …
Human Services announced the formation of the Office of Long COVID Research and …
Effectiveness of antiviral therapy on long COVID: a systematic review and meta-analysis
Antiviral treatment reduces the severity and mortality of SARS-CoV-2 infection; however, its
effectiveness against long COVID-19 is unclear. This study aimed to evaluate the …
effectiveness against long COVID-19 is unclear. This study aimed to evaluate the …
The efficacy of antivirals, corticosteroids, and mAbs as acute COVID treatments in reducing the incidence of long COVID: a Systematic Review and meta-analysis
G Sun, K Lin, J Ai, W Zhang - Clinical Microbiology and Infection, 2024 - Elsevier
Background Whether treatment during acute COVID results in protective efficacy against
long COVID incidence remains unclear. Objectives To assess the relationship between …
long COVID incidence remains unclear. Objectives To assess the relationship between …
[HTML][HTML] Early use of oral antiviral drugs and the risk of post COVID-19 syndrome: a systematic review and network meta-analysis
J Jiang, Y Li, Q Jiang, Y Jiang, H Qin, Y Li - Journal of Infection, 2024 - Elsevier
Objectives This study aimed to determine the association of early use of oral antiviral drugs
(including nirmatrelvir-ritonavir and molnupiravir) with the risk of PCC and compare the …
(including nirmatrelvir-ritonavir and molnupiravir) with the risk of PCC and compare the …
Clinical effectiveness of oral antiviral agents for treating non-hospitalized COVID-19 patients with chronic kidney disease
CC Chen, CY Huang, JY Wu, MY Liu… - Expert Review of Anti …, 2024 - Taylor & Francis
Objectives This study examined the effectiveness of nirmatrelvir plus ritonavir (NMV-r) and
molnupiravir (MOV) in treating COVID-19 among chronic kidney disease (CKD) patients …
molnupiravir (MOV) in treating COVID-19 among chronic kidney disease (CKD) patients …